TCM
VIVO

Teza Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

Teza Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-10,425
Closed -$185K – 612
2016
Q4 		$185K Buy
+10,425
New +$183K 0.26% 180

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Teza Capital Management's VIVO Position: Q1 2017 in Review

Teza Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q1 2017, closing a stake of 10,425 shares — an estimated $185K sold.

Teza Capital Management first reported a position in VIVO in Q4 2016 and held it in 1 quarter. The position peaked at $185K in Q4 2016. 165 funds tracked by Wall St. Rank hold VIVO as of Q1 2017.

  • Teza Capital Management reported no remaining Meridian Bioscience Inc position as of Q1 2017 after selling out during the quarter.
  • Teza Capital Management sold 10,425 Meridian Bioscience Inc shares in Q1 2017, an estimated $185K.
  • Teza Capital Management first reported a position in Meridian Bioscience Inc in Q4 2016 and held it in 1 quarter.
  • Teza Capital Management's Meridian Bioscience Inc position peaked at $185K in Q4 2016.
  • 165 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2017.

Based on Teza Capital Management's 13F filing for Q1 2017, filed 4 May 2017.